Neurotechnology nearer than you think: Morgan Stanley estimates $400B TAM for BCIs across 3 million US adults
Summary
Morgan Stanley published analysis estimating the total addressable market for brain-computer interfaces at $400 billion across three million US adults — a figure covering motor restoration, communication, vision, and cognitive enhancement applications. The estimate was cited in a Clinical Trials Arena analysis noting that BCIs are transitioning from science fiction curiosities to promising neurotechnology on the verge of commercialization, with multiple clinical trials showing safety and early efficacy and a growing market driven by Neuralink, Synchron, Blackrock Neurotech, and Paradromics.
Why it matters
Morgan Stanley's $400B BCI TAM estimate is the single largest market sizing published by a major investment bank for any single medical technology category. While this figure represents a long-term scenario rather than near-term addressable market, its publication by a major investment bank legitimizes BCI as a multi-generational investment thesis at the scale of oncology drugs or cardiovascular devices — not a niche neurotech segment.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial